-
Sarepta, Codiak Nix Exosome Therapy Development Pact
Friday, October 8, 2021 - 1:02pm | 206Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option agreement early. The termination will be effective as of December 3, 2021. The agreement focused on using exosomes...
-
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Tuesday, September 14, 2021 - 6:48am | 353Read More...Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics Inc. The Aspiro trial was testing AT132, gene therapy for a rare neuromuscular disease, X-linked Myotubular Myopathy (...
-
Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders
Tuesday, May 11, 2021 - 9:05am | 198Read More...Biogen Inc (NASDAQ: BIIB) and Capsigen Inc have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids with the potential to deliver gene therapies for various CNS and neuromuscular disorders. As a part of the...
-
Argenx's Efgartigimod US Application In Neuromuscular Disorder Accepted For Review
Tuesday, March 2, 2021 - 6:40am | 161Read More...The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle...
